OMER · Omeros Corporation · Stock research

Current Thesis

The European binary already detonated to the downside. On 2026-06-25 the EMA's CHMP adopted a negative opinion on narsoplimab in TA-TMA; the disclosure landed 2026-06-26 and knocked shares 19.12% ($2.05) to $8.67. Since then the tape has repaired rather than broken — roughly $9.69 as of 2026-07-17 after a 5–6% session, helped by the permanent CMS J-code (J1289) going live 2026-07-01. What's left is a US-only orphan launch with a clean reimbursement pathway, $135.3M of cash, and a low-odds European re-examination. The next thing that matters is the 2026-08-13 Q2 print: consensus wants roughly $11.6M in net sales against a $9.9M Q1 base. That number, not the EU appeal, sets the next 90 days. The narrative is in repair phase — the accelerating leg fired between October 2025 and December 2025 and is behind the stock.

Bullish and bearish views on Omeros Corporation

The model's bull view on Omeros Corporation (OMER), in brief: The US franchise is untouched and reimbursement just got easier. The bear view: The upside binaries are spent and the last one printed against the stock. Both cases follow in full.

Bull Case

• The US franchise is untouched and reimbursement just got easier. CMS assigned permanent HCPCS J-code J1289 (announced 2026-04-16, effective 2026-07-01), replacing miscellaneous-code billing with a product-specific pathway across Medicare and commercial payors. Launch-stage orphan biologics routinely see a step-up in ordering velocity once a permanent J-code removes the prior-auth friction — the Q2 and Q3 prints are the first read on whether that shows up.
• Q1 shipped far ahead of the Street. Gross product sales of $11.1M and net $9.9M for the quarter ended 2026-03-31, against sell-side estimates near $4.1M. YARTEMLEA holds the only FDA-approved label in TA-TMA (approved 2025-12-23, launched January 2026, ages two and up). FY2026 consensus sits near $78.6M.
• Balance sheet no longer carries a solvency discount. $135.3M cash and investments at 2026-03-31, the 2026 notes retired at maturity in February 2026, leaving $70.8M of 2029 convertibles outstanding. The going-concern framing that pinned shares near $3.34 is gone.
• Novo Nordisk validation with milestone optionality. The asset deal closed 2025-12-01 with $240M cash upfront, roughly $100M of near-term milestones still eligible, and up to $2.1B in total consideration plus tiered royalties on the zaltenibart/OMS906 PNH program, which Novo funds and runs the global Phase 3 for.
• Sell-side hasn't capitulated. H.C. Wainwright cut its target to $33 from $40 on 2026-06-26 while reaffirming Buy; three covering analysts average $33. The rejection is being priced as a European revenue haircut rather than a thesis kill.

Bear Case

• The upside binaries are spent and the last one printed against the stock. Down roughly 45% from the $17.65 high, with the Novo deal and FDA approval seven months in the rear-view and the EU decision now a rejection under appeal. There is no floating catalyst of comparable size left in the next quarter.
• CHMP's objections are structural. Coverage of the opinion cites the absence of a placebo or comparator arm, confounding concomitant medications, and insufficient pediatric data as why the pivotal study failed to convince. Those are trial-design problems an Ad Hoc Expert Group cannot re-run. CHMP reversals on re-examination are uncommon, and a favorable AHEG read is not the base case.
• Headline valuation is an accounting illusion. The trailing P/E near 8x rests on Q1 net income of $56.1M / $0.78 EPS, which included a $73.1M non-cash mark-to-market gain on the 2029 notes' embedded derivative. Q4 2025's profit similarly rode a roughly $237.6M one-time Novo transaction gain. Strip both and the company loses money on single-digit-millions of quarterly product revenue.
• Litigation overhang opened in July. The Schall Law Firm (2026-07-06), Portnoy (2026-07-13), Pomerantz, and Bronstein Gewirtz & Grossman have all announced investigations tied to the 2026-06-26 drop. Investigation-stage press releases are cheap and frequently go nowhere, but they cap institutional appetite while they sit open.
• Ultra-orphan ceiling, now US-only. TA-TMA is a narrow HSCT-complication population. Losing Europe caps the addressable market to US transplant centers, and one quarter at $9.9M is not enough to model a durable slope.

Setup & Price Structure

The 2026-06-26 gap sliced the $8.50 shelf that had contained the post-approval consolidation for months, with the session closing at $8.67. Three weeks later price has recovered into the $9.30–$10.00 band — trading near $9.69 on 2026-07-17 after prints around $9.28 on 2026-07-02 and a prior close of $10.01 in mid-July. That is a base being rebuilt above the gap low, which is constructive, but it is repair work under a broken structure, not a breakout. Overhead supply from the pre-gap $10.50–$11.00 range is the first real test; the $13–$14 zone is where a genuine trend reclaim would register. Market cap $701M, beta 2.55, average volume around 1.2M shares. With the 52-week range spanning $3.34 to $17.65, position sizing has to respect the fact that this name moves 20% on a single headline. Chasing the recovery bounce into a print 25 days out is the wrong side of the risk/reward; the setup earns attention on either a hold of the $9.30 area with the ramp confirmed, or a clean reclaim of the pre-gap shelf on volume.

Catalyst Calendar (next 30 days)

• 2026-08-13 — Q2 2026 financial results. The number that matters: net product sales versus the $9.9M Q1 base and roughly $11.6M consensus. Also watch product gross margin, cash burn ex-derivative noise, and any FY2026 guide against the $78.6M consensus. A thesis that isn't earnings-driven should not be carrying fresh exposure into this print; blackout window opens ~2026-08-10.
• ~2026-08-13 (same call) — Management commentary on the EU re-examination timeline and whether the AHEG has been convened. No standalone date is published; the filing window ran 15 days from the 2026-06-25 opinion, so the request should already be lodged.
• No CHMP re-examination outcome expected in this window. Standard re-examination procedures run roughly four months, putting a second opinion around Q4 2026. Any date circulated before then is speculation.

Elapsed catalysts

• Ongoing, July–August — First reporting period reflecting the J1289 J-code effective 2026-07-01. Any interim commentary on transplant-center ordering or new account adds is the leading indicator ahead of the Q3 print. (passed 39d ago)

What Would Change Our Mind

• Upside: Q2 net sales materially above the $11.6M consensus with expanding gross margin and a raised FY2026 guide — that converts the story from a spent binary into a launch-ramp compounder and justifies re-rating the $33 street target. A weekly close reclaiming ~$13 on volume would confirm it technically. A Novo milestone trigger against the ~$100M near-term pool is a second, unscheduled upside path.
• Downside: A weekly close below $8.00 gives back the entire post-gap repair and puts the $3.34–$8.00 vacuum back in play. Q2 net sales at or below $9.9M would say the launch pulled forward stocking rather than building a base. A denied re-examination with no offsetting ramp acceleration removes the last optionality bullet. Escalation of the July law-firm investigations into a filed complaint with specific allegations about pre-opinion disclosures would be a separate, harder problem.
• Framing: With two catalysts fired positive and one negative, the residual re-examination is not an accelerating catalyst and should not be sized as one. This sits in the beginner-trap matrix as a "was a good idea in December" name — the 5x from $3.34 rewarded people who owned it before the approval, not people buying the bounce off the rejection. The correct stance is to let the print resolve the ramp question rather than pay up for the recovery in advance.

Correlation Notes

• Complement-pathway and MASP/orphan biotech peers — moves with the small-cap rare-disease complex on FDA and EMA headlines, but the TA-TMA label is sole-source, so peer read-throughs are weak. Idiosyncratic regulatory risk dominates.
• Novo Nordisk (NVO) — indirect exposure through the zaltenibart/OMS906 PNH program. Novo funds and runs the Phase 3, so a Novo pipeline reprioritization would hit the milestone stream without any OMER-specific news.
• US–EU regulatory divergence — the FDA-approved / CHMP-rejected split is a recurring 2026 pattern for single-arm oncology and orphan programs. Names carrying EU applications on single-arm data trade with elevated event risk regardless of US status.
• Beta 2.55 to the broad tape. In a risk-off small-cap biotech drawdown this name gives back multiples of the index. Not a diversifier; a leveraged expression of the same risk appetite.
• Retail flow — StockTwits and Reddit attention concentrates around regulatory dates and earnings. Expect a volume spike into 2026-08-13 that is sentiment-driven and unrelated to the underlying ramp slope.